Dantari Debuts With $47 Million Series A To Advance Best-In-Class Targeted Medicines For Solid Tumors

Dec 08, 2022•about 3 years ago

Amount Raised

$47 Million

Round Type

series a

Thousand OaksTherapeuticsBiotechnology

Investors

Alexandria Venture InvestmentsCorner VenturesWestlake Village Bio Partners

Description

Dantari, Inc. ("Dantari"), a clinical-stage biotechnology company developing best-in-class targeted therapeutics for the treatment of cancers and other diseases, today announced its emergence from stealth mode with $47 million Series A financing. The Series A financing was led by Westlake Village BioPartners ("Westlake") and included participation from Corner Ventures, Alexandria Venture Investments, and Caltech. The Company also announced the appointment of Richard A

Company Information

Company

Dantari

Location

Thousand Oaks, California, United States

About

Dantari, Inc. is a clinical-stage biotechnology company developing best-in-class targeted therapeutics for the treatment of cancers and other diseases. Dantari is advancing a pipeline of T-HDC (Targeted High-capacity Drug Conjugate) chemotherapeutic agents starting with DAN-222 and next-generation ADC therapeutics T-HDC technology originating from Caltech. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR), and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. Visit us at www.dantari.com to learn more.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends